Who knew test tubes could make for such good business? Vimta Labs just clocked its highest-ever quarterly revenue — ₹104.5 crore — proving that science isn’t just about experiments, it’s about execution. While AI startups burn cash, this Hyderabad-based CRO quietly churns out margins north of 35%. CEO Harita Vasireddi sounded calm and clinical, announcing growth across pharma and food testing while hinting that their biologics dream is almost ready to pipette its first molecule. If boring is the new bold, Vimta just patented it. Stick around — the biologics play and WHO audits make this one a nerd’s fairytale.
At a Glance
- Revenue ₹104.5 crore– Broke the ₹100-crore ceiling without breaking a sweat.
- EBITDA ₹36.9 crore (35.3%)– Margin goals; scientists could teach CFOs a thing or two.
- PAT ₹19.9 crore (19.1%)– Profit curve smoother than lab glassware.
- H1 Revenue ₹203.8 crore– Up 26.6% YoY; clearly, R&D pays off.
- Cash ₹54.5 crore, Debt-free– Balance sheet cleaner than a sterilized beaker.
- CapEx ₹47 crore (H1)– Building for biologics glory, molecule by molecule.
Management’s Key Commentary
“We recorded our highest-ever quarterly revenue crossing ₹100 crores.”(Translation: We’re no longer the small-cap underdog — we’ve joined the grown-ups’ table.)
“Pharma testing and food testing led the growth.”(The lab smells of profits — and maybe biscuits and bioreactors.)
“WHO audit passed successfully.”(That’s corporate-speak for ‘Regulators love us.’)
“The biologics R&D project is on schedule; commercialization by Q1FY27.”(They’re building the future, one protein at a time.)😏
“CapEx is across pharma, food, and electronics — we’re future-ready.”(Translation: Diversified enough to survive a science apocalypse.)
“Margins are very good; don’t expect higher ones.”(The CFO basically said, ‘Enjoy it while it lasts.’)
Numbers Decoded
| Metric | Q2FY26 | Q2FY25 | YoY % | Comment |
|---|---|---|---|---|
| Revenue | ₹1,045 mn | ₹854 mn | +22.3% | Strong across pharma & food |
| EBITDA | ₹369 mn | ₹306 mn | +20.6% | Margins holding steady |
| PAT | ₹199 mn | ₹170 mn | +17.1% | Profits bubbling nicely |
| PAT Margin | 19.1% | 19.9% | – | Consistent, clinical |
| H1 Revenue | ₹2,038 mn | ₹1,610 mn | +26.6% | Sustained momentum |
| H1 EBITDA Margin | 35.5% | 35.4% | — | Scientists clearly hate volatility |
| CapEx (H1) | ₹47 Cr | — | — | Halfway through ₹100 Cr plan |
| Net Debt | ₹0 | ₹0 | — | Pure, unlevered science |
Overseas business now ~32% of revenue. Exporting not just samples, but profits.
Analyst Questions
Q:“Now that you hit ₹100 crore revenue, any constraints?”A:“No capacity issues. Infrastructure ready; people next.”(Translation: Give us orders, not oxygen.)
Q:“Phase 2 utilization?”A:“About 50–60% already in use.”(They build, then fill — like a scientist with patience.)
Q:“How’s the clinical trials pipeline?”A:“Two new trials started; one already filed in Europe.”(Finally, a CRO that delivers, not just ‘files paperwork.’)
Q:“Competition from Eurofins, SGS?”A:“They’re in India; we still grow faster.”(Homegrown precision meets global hustle.)
Q:“BIOSECURE Act impact?”A:“Global biotechs are coming to India — we’re already talking to two.”(Global politics = Indian opportunity.)
Guidance & Outlook
Management aims
